Intercept Pharmaceuticals is a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare and serious liver diseases. As a wholly owned subsidiary of Alfasigma S.p.A., we have the resources and expertise to bring life-changing treatments to patients in need.
At Intercept, we are driven by our mission to improve the lives of those living with liver diseases. Our focus is on developing treatments for primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH), two conditions that currently have limited treatment options. By addressing these unmet needs, we are making a significant impact on the liver disease community.
Our team is comprised of highly skilled and passionate individuals who are dedicated to advancing liver disease treatments. We have a deep understanding of the complexities of liver diseases and are committed to delivering innovative solutions that can make a real difference in patients' lives.
Located in New Jersey, our corporate headquarters serves as the hub for our global operations. We have a strong presence in the biopharmaceutical industry and are continually expanding our reach to bring our therapies to patients around the world.
At Intercept, we value transparency, integrity, and collaboration. We work closely with patients, healthcare professionals, and advocacy groups to gain a better understanding of their needs and ensure that our treatments are meeting the highest standards of quality and safety.
We are proud of our track record of success and are dedicated to continuous innovation and improvement. Through our research and development efforts, we are constantly exploring new ways to improve the lives of those affected by liver diseases.
To learn more about Intercept Pharmaceuticals and our commitment to the liver disease community, please visit our website at www.interceptpharma.com and follow us on social media at @InterceptPharma. Together, we can make a lasting impact on the lives of those living with rare and serious liver diseases.